Larisa Reyderman
Eisai (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Cancer Treatment and Pharmacology, Computational Drug Discovery Methods, Colorectal Cancer Treatments and Studies, Cholinesterase and Neurodegenerative Diseases
Most-Cited Works
- → Lecanemab in Early Alzheimer’s Disease(2022)4,787 cited
- → A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody(2021)772 cited
- → Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules(2003)368 cited
- → Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study(2022)264 cited
- → ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease(2023)102 cited
- → Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects(2011)93 cited
- → The Toxicity of SCH 351591, a Novel Phosphodiesterase-4 Inhibitor, in Cynomolgus Monkeys(2004)75 cited
- → First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers(2020)70 cited
- → Lack of Clinically Relevant Interaction Between Desloratadine and Erythromycin(2002)62 cited
- → Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe*(2004)61 cited